Recent Company News

• 01:05 AM ET Feb 04, 2026
  

  UCB announced three-year data from the BE HEARD trials^ for BIMZELX (bimekizumab) in moderate to severe HS (€261.00, 0.00)

• 03:47 AM ET Feb 03, 2026
  

  UCB upgraded to buy from accumulate at KBC (pre-European open) (€263.30, +2.70)

• 07:01 AM ET Jan 30, 2026
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation under exceptional circumstances for Kygevvi (€254.20, +1.20)

• 04:16 PM ET Jan 28, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:33 AM ET Jan 14, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:07 PM ET Jan 27, 2026
  

  NICE recommends Biogen's Tysabri, Sandoz's Tyruko to treat highly active relapsing-remitting multiple sclerosis after disease-modifying therapy

• 05:04 PM ET Jan 27, 2026
  

  HHS/CMS announce 15 additional drugs selected for Medicare drug price negotiations under IRA

• 04:14 AM ET Jan 16, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (133 total)

• 11:30 AM ET Jan 14, 2026
  

  Transcript Intelligence: UCB at J.P. Morgan Healthcare Conference